Viking Therapeutics Shares Rise on Positive Obesity Drug Data
Viking Therapeutics (VKTX) saw its stock rise more than 30% in premarket trading after announcing positive top-line results for its obesity drug candidate, VK2735. The GLP-1/GIP receptor agonist achieved a weight loss of 22%, with promising indications that the effects can be maintained using less frequent dosing regimens. The data highlights Viking Therapeutics' potential in developing effective and convenient treatments for obesity, which is an area attracting significant investor interest due to recent successes in similar drug classes. The results have generated optimism among investors regarding VKTX's pipeline progress and future commercial viability.
Tickers: $VKTX
Topics: biotech GLP-1/GIP agonist stock movement weight loss drug